「head」の検索結果
27件：21～25件目を表示
もしかして
-
Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
apan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is pleased to announc...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406.pdf -
apan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is pleased to announc...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406_0.pdf -
t Receptor Potential cation channel subfamily V member 1 Inhibition Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is pleased to announc...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf